Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NO COVID-19 chloroquine antiviral effect trial
2020-001010-38Phase 4Terminated
- Sponsor
- Akershus University Hospital
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of hydroxychloroquine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Akershus University Hospital. Primary endpoint: Rate of decline in SARS-CoV-2 viral load. Started Mar 2020; status: terminated.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001010-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001010-38.